Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers(Genmab (Netherlands)), Paul W.H.I. Parren(Leiden University Medical Center)
The Journal of Immunology
December 28, 2010
10.4049/jimmunol.1003032
Cited by 1,013

Related Papers

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
|mAbs|2015|502
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
|The Journal of Immunology|2004|149
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
|Molecular Cancer Therapeutics|2016|131
Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action
|Cancer Research|2006|124
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
|Blood Cancer Journal|2020|70